Home>Topics>Funds>SPDR S&P Biotech

SPDR S&P Biotech

  1. All
  2. Commentary
  3. ETF Reports
  4. Headlines
  1. XBI SPDR S&P Biotech ETF ETF Analysis, Report, Research, 5 Star Rating – Morningstar

    ETF Reports

    Tue, 2 Sep 2014

    for these products in the U.S. XBI 's 0.35% expense ratio is tied ..... like Amgen and Celgene. Thus, XBI 's average market cap, on a holdings ..... exposure to the industry in one trade. SPDR S & P Biotech XBI offers exposure to the promising

  2. FBT First Trust NYSE Arca Biotech ETF ETF Analysis, Report, Research, 5 Star Rating – Morningstar

    ETF Reports

    Tue, 2 Sep 2014

    relative to other biotech ETFs--in particular, SPDR S & P Biotech XBI , which charges 0.35%. FBT's estimated holding ..... biotech companies can consider four other ETFs. SPDR S & P Biotech XBI (0.35% expense ratio) holds a fairly concentrated

  3. IBB iShares Nasdaq Biotechnology ETF Analysis, Report, Research, 5 Star Rating – Morningstar

    ETF Reports

    Tue, 2 Sep 2014

    cheaper ETF options exist. For instance, both SPDR S & P Biotech XBI and Market Vectors Biotech ETF BBH charge just 0 ..... seeking exposure solely to biotechs also can consider SPDR S & P Biotech XBI (0.35% expense ratio), which is a fairly concentrated

  4. Today's Market: Red Hot Biotech And Big Pharma Names To Watch

    Headlines

    Fri, 29 Aug 2014

    By Matthew Smith : A busy week is about to come to an end, but not before we have learned a lot about the strength of this market and just how resilient it is. Some will point to the weak volume over the past few sessions, but that is to be expected this time of year. Factoring in that volatility

  5. Competition And Momentum Weighing On Clovis Oncology

    Headlines

    Sat, 23 Aug 2014

    actually been all that bad for biotech, as the S&P Biotech ETF (NYSEARCA: XBI ) has outperformed the S&P 500 by about six or seven points. Whether or not the XBI is a great benchmark for the biotech industry is beside the point, though

  6. IHE iShares US Pharmaceuticals ETF Analysis, Report, Research, 5 Star Rating – Morningstar

    ETF Reports

    Mon, 5 May 2014

    tracking other health-care subsectors show numbers in the 20% to 25% range. For instance, the equal-weight SPDR S & P Biotech XBI has a five-year volatility of return of 24.5%. Meanwhile, the market-cap-weighted iShares US Healthcare

  7. XPH SPDR S&P Pharmaceuticals ETF ETF Analysis, Report, Research, 5 Star Rating – Morningstar

    ETF Reports

    Mon, 5 May 2014

    tracking other health-care subsectors show numbers in the 16% to 25% range. For instance, the equal-weight SPDR S & P Biotech XBI has a five-year volatility of return of 24.2%. Meanwhile, the market-cap-weighted iShares US Healthcare

  8. T/A May 2014 -- SPY "Home On The Range"

    Commentary

    Wed, 30 Apr 2014

    Some plays like XLI are still Bullish. Momentum stocks as represented by QQQ and XBI have broken down and are in a Bearish IT for now. My computer considers her XBI trade management as the “Greatest Escape Since Dunkirk” but she tends to be

  9. April T/A - Sell before May and go away?

    Commentary

    Fri, 28 Mar 2014

    fate of the bull market a little. Again, not enough evidence to pronounce it dead yet though. Speaking of Biotechs This is XBI , and it looks like a heck of a blow off top from where we sit today. I advocated buying if you were a bull yesterday; today

  10. From Barron’s, March 24, 2014 (Part 2)

    Commentary

    Sat, 22 Mar 2014

    bond funds. Pg 35: Biotechs are hot and the related ETFs [ IBB, XBI ] are attracting huge inflows [YTD inflows are already more than those for entire 2013]. The P/E of XBI is 33 excluding negative earnings and -19 [ yes, minus 19 ] after including

« Prev12Next »
Content Partners